白蛋白结合型紫杉醇治疗中晚期卵巢癌患者的效果评估  

Efficacy evaluation of albumin-bound paclitaxel in the treatment of advanced ovarian cancer

作　　者：戴萍[1] 仇为民[1] 丁倩 冯媛媛 Dai Ping;Qiu Weimin;Ding Qian;Feng Yuanyuan(Department of Pharmacy,Jiangdu People's Hospital of Yangzhou,Jiangdu 225200,China)

机构地区：[1]扬州市江都人民医院药剂科,江苏江都225200

出　　处：《实用妇科内分泌电子杂志》2021年第28期54-56,共3页Electronic Journal of Practical Gynecological Endocrinology

摘　　要：目的探究中晚期卵巢癌患者采取白蛋白结合型紫杉醇治疗的临床效果。方法选取58例中晚期卵巢癌患者,遵循随机数字表法分为对照组(28例)与研究组(30例)。对照组患者采取紫杉醇治疗,研究组患者采取白蛋白结合型紫杉醇治疗。比较两组患者治疗效果、治疗前后血清肿瘤标记物水平及不良反应发生情况。结果研究组临床治疗总有效率和疾病控制率均高于对照组,差异有统计学意义(P<0.05)。治疗前,两组糖类抗原(CA)125、CA199水平比较,差异无统计学意义(P>0.05);治疗后,研究组CA125、CA199水平均低于对照组,差异有统计学意义(P<0.05)。研究组治疗期间不良反应率26.67%显著低于对照组64.29%,差异有统计学意义(P<0.05)。结论中晚期卵巢癌患者采取白蛋白结合型紫杉醇治疗的临床效果确切,能够有效改善患者血清肿瘤标记物水平,并降低药物不良反应,值得临床推广与应用。Objective To explore the clinical effect of albumin-binding paclitaxel treatment in patients with advanced ovarian cancer.Methods 58 patients with advanced ovarian cancer were randomly divided into control group(28 cases)and study group(30 cases).Patients in the control group were treated with paclitaxel,while patients in the study group were treated with albuminbound paclitaxel.The treatment effect,serum tumor marker levels and adverse reactions before and after treatment were compared between the two groups.Results The total effective rate and disease control rate of the study group were higher than those of the control group,and the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in the levels of carbohydrate antigen(CA)125 and CA199 between the two groups(P>0.05).After treatment,the levels of CA125 and CA199 in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The adverse reaction rate of the study group was 26.67%,which was significantly lower than that of the control group(64.29%),and the difference was statistically significant(P<0.05).Conclusion The clinical effect of albumin-bound paclitaxel treatment in patients with advanced ovarian cancer is exact,which can effectively improve the level of serum tumor markers and reduce adverse drug reactions,which is worthy of clinical promotion and application.

关 键 词：中晚期卵巢癌 白蛋白结合型紫杉醇 临床效果 血清肿瘤标记物 不良反应 

分 类 号：R737.31[医药卫生—肿瘤]